| 203.83 5.29 (2.66%) | 06-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 239.93 |
1-year : | 280.23 |
| Resists | First : | 205.41 |
Second : | 239.93 |
| Pivot price | 195.26 |
|||
| Supports | First : | 193.81 |
Second : | 186.63 |
| MAs | MA(5) : | 196.97 |
MA(20) : | 195.61 |
| MA(100) : | 157.8 |
MA(250) : | 140.33 |
|
| MACD | MACD : | 5.8 |
Signal : | 6.6  |
| %K %D | K(14,3) : | 79.7 |
D(3) : | 62.4 |
| RSI | RSI(14): 67.9 |
|||
| 52-week | High : | 205.41 | Low : | 101 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DVA ] has closed It is unclear right now based on current values. 40.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 200.34 - 201.3 | 201.3 - 202.17 |
| Low: | 194.77 - 195.9 | 195.9 - 196.93 |
| Close: | 196.69 - 198.54 | 198.54 - 200.21 |
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Thu, 11 Jun 2026
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Thu, 11 Jun 2026
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
Thu, 11 Jun 2026
DaVita expands comprehensive kidney care through dialysis services - MSN
Wed, 10 Jun 2026
DaVita Stock Gains From Integrated Kidney Care and CKCC Progress - TradingView
Wed, 10 Jun 2026
Are Investors Undervaluing DaVita (DVA) Right Now? - Yahoo Finance
Wed, 10 Jun 2026
DaVita Inc. $DVA Stake Lifted by Los Angeles Capital Management LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 64 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 50.5 (%) |
| Held by Institutions | 52 (%) |
| Shares Short | 5,680 (K) |
| Shares Short P.Month | 5,910 (K) |
| EPS | 10.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.41 |
| Profit Margin | 5.6 % |
| Operating Margin | 13.8 % |
| Return on Assets (ttm) | 7.5 % |
| Return on Equity (ttm) | 80.9 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 69.94 |
| Sales Per Share | 215.6 |
| EBITDA (p.s.) | 43.46 |
| Qtrly Earnings Growth | 43.5 % |
| Operating Cash Flow | 2,030 (M) |
| Levered Free Cash Flow | 1,000 (M) |
| PE Ratio | 19.64 |
| PEG Ratio | 0.6 |
| Price to Book value | -17.88 |
| Price to Sales | 0.94 |
| Price to Cash Flow | 6.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|